Hemostemix Inc.
HEM
Rank in Stocks
#32260
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.0477059
Market Cap
$10.09M
Change (1 day)
18.18%
Change (1 year)
-34.38%
Country
CA
Trade Hemostemix Inc. (HEM)
Category
Healthcare
Stock split history for Hemostemix Inc. (HEM)
Hemostemix Inc. stock (symbol: HEM) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One HEM share bought prior to Oct 20, 2026 would equal to 0 HEM shares today.
The most recent stock split occurred on Oct 20, 2026.
One HEM share bought prior to Oct 20, 2026 would equal to 0 HEM shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
